Cuba's Center of Molecular Immunology is currently evaluating the progress of a clinical trial using the 2C12 molecule in patients suffering from advanced melanoma.
The clinical trial will be conducted in just two provinces across the country: in Havana, at the National Institute of Oncology and Radiobiology and the Hermanos Ameijeiras Clinical-Surgical Hospital; and in Villa Clara, at the Celestino Hernández Robau Oncology Hospital.
This scientific breakthrough from the largest island of the Antilles is part of ongoing research aimed at expanding therapeutic alternatives against cancer.
The therapeutic candidate, designated 2C12, exhibits properties similar to pembrolizumab, one of the treatments used internationally to stimulate the immune system's response against tumor cells.
In this first stage, the Granma newspaper specifies, the clinical trial will focus on individuals with advanced melanoma—that is, cases of skin cancer that cannot be treated surgically or have metastasized to other parts of the body.
The 2C12 molecule is administered in cases of advanced metastatic melanoma that are ineligible for surgery, in patients with metastatic lung cancer undergoing second-line treatment, and in patients with refractory Hodgkin's lymphoma.
The development of this alternative responds to the need for accessible therapeutic options in the face of the exorbitant costs of certain oncology medications on the international market.
It also addresses the difficulties Cuba faces in acquiring them as a result of the economic, commercial, and financial blockade imposed by the United States for over 60 years.
(Taken from Prensa Latina)
CubaPLUS Latinos
CubaPLUS Guyana
CubaPLUS Travel